The expanded analysis confirmed DFS benefits across various subgroups, including UTUC, and highlighted that adjuvant nivolumab significantly improves DFS, particularly among patients with higher PD-L1 expression [17,18]. This evidence concerns the gene CD274 and renal pelvis/ureter urothelial carcinoma.